Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 730.08 M
The data is delayed by 15 minutes.
Description: Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was found
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||15.64 M||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||526.88%||Sales Growth - Q/Q||548.38%||P/E|
|P/E To EPS Growth||P/S||14.45||P/BV||7.1||Price/Cash Per Share|
|Price/Free Cash Flow||-52.57||ROA||1.66%||ROE||2.09%||ROI|
|Current Ratio||4.8||Quick Ratio||4.72||Long Term Debt/Equity||Debt Ratio||0.26|
|Gross Margin||71.95%||Operating Margin||2.84%||Net Profit Margin||4.26%||Dividend Payout Ratio|
|Cash From Financing Activities||55.29 M||Cash From Investing Activities||3.95 M||Cash From Operating Activities||17.96 M||Gross Profit||30.36 M|
|Net Profit||19.7 M||Operating Profit||20.09 M||Total Assets||129.93 M||Total Current Assets||129.79 M|
|Total Current Liabilities||27.05 M||Total Debt||Total Liabilities||27.05 M||Total Revenue||36.31 M|
|High 52 week||67.49||Low 52 week||36.72||Last close||61.99||Last change||2.07%|
|RSI||86.41||Average true range||1.81||Beta||1.24||Volume||253.51 K|
|Simple moving average 20 days||6.76%||Simple moving average 50 days||7.94%||Simple moving average 200 days||20.46%|
|Performance Week||5.28%||Performance Month||5.5%||Performance Quart||13.89%||Performance Half||23.98%|
|Performance Year||3.08%||Performance Year-to-date||53.86%||Volatility daily||1.68%||Volatility weekly||3.75%|
|Volatility monthly||7.68%||Volatility yearly||26.62%||Relative Volume||311.49%||Average Volume||149.42 K|
|New High||New Low|
2020-06-03 03:31:30 | Edited Transcript of EGRX earnings conference call or presentation 11-May-20 12:30pm GMT
2020-05-26 16:30:00 | Eagle Pharmaceuticals to Present at June Investor Conferences
2020-05-14 11:50:00 | Eagle Pharmaceuticals, Inc. NASDAQ:EGRX Analysts Just Slashed This Year's Estimates
2020-05-11 12:30:48 | Eagle Pharmaceuticals Inc EGRX Q1 2020 Earnings Call Transcript
2020-05-11 08:35:12 | Eagle Pharmaceuticals EGRX Q1 Earnings Surpass Estimates
2020-05-11 08:14:14 | Eagle Pharmaceuticals: Q1 Earnings Insights
2020-05-11 07:22:03 | A Look At The Fair Value Of Eagle Pharmaceuticals, Inc. NASDAQ:EGRX
2020-05-11 06:50:00 | Eagle Pharmaceuticals Reports First Quarter 2020 Results
2020-05-08 08:41:12 | Why Eagle Pharmaceuticals EGRX Might Surprise This Earnings Season
2020-05-07 06:07:10 | 3 Medical Product Stocks Set to Beat This Earnings Season
2020-05-04 06:50:00 | Eagle Pharmaceuticals Advances Novel and Proprietary Formulation of Fulvestrant Product Candidate EA-114; Company to Request Additional Meeting with U.S. Food and Drug Administration "FDA"
2020-04-29 16:30:00 | Eagle Pharmaceuticals to Discuss First Quarter 2020 Financial Results on May 11, 2020
2020-04-28 12:33:04 | Earnings Preview: Eagle Pharmaceuticals EGRX Q1 Earnings Expected to Decline
2020-04-16 17:24:10 | Covid Report: Gilead Pops On Promising Sneak Peek For Coronavirus Drug
2020-04-11 09:25:13 | What Is Eagle Pharmaceuticals's NASDAQ:EGRX P/E Ratio After Its Share Price Rocketed?
2020-03-22 15:34:06 | Edited Transcript of EGRX earnings conference call or presentation 2-Mar-20 1:30pm GMT
2020-03-10 07:55:20 | What Is Eagle Pharmaceuticals's NASDAQ:EGRX P/E Ratio After Its Share Price Tanked?
2020-03-02 08:15:01 | Eagle Pharmaceuticals EGRX Surpasses Q4 Earnings and Revenue Estimates
2020-03-02 06:50:00 | Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results
2020-02-24 12:30:05 | Earnings Preview: Eagle Pharmaceuticals EGRX Q4 Earnings Expected to Decline
2020-02-13 07:50:01 | Eagle Pharmaceuticals NASDAQ:EGRX Has A Pretty Healthy Balance Sheet
2020-02-10 09:54:00 | Eagle Pharmaceuticals Receives Final FDA Approval for PEMFEXY™ Pemetrexed for Injection
2020-01-09 08:40:01 | Tyme Initiates Dosing in Pivotal Pancreatic Cancer Study
2020-01-09 06:50:00 | Eagle Pharmaceuticals Resubmits NDA for RYANODEX for Exertional Heat Stroke
2020-01-08 10:18:03 | Tyme Out-Licenses Cancer Candidate to Eagle Pharma, Stock Up
2020-01-08 08:16:25 | Is Eagle Pharmaceuticals, Inc.'s NASDAQ:EGRX ROE Of 15% Concerning?
2020-01-07 09:25:00 | Tyme stock rises on Eage collaboration for cancer drug
2019-12-23 06:50:00 | Eagle Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
2019-12-11 11:25:36 | Eagle Pharmaceuticals Inc EGRX: Are Hedge Funds Right About This Stock?
2019-11-20 06:50:00 | Eagle Pharmaceuticals to Present at 31st Annual Piper Jaffray Healthcare Conference
2019-11-18 21:32:30 | Edited Transcript of EGRX earnings conference call or presentation 12-Nov-19 1:30pm GMT
2019-11-12 08:15:01 | Eagle Pharmaceuticals EGRX Q3 Earnings and Revenues Lag Estimates
2019-11-12 06:51:00 | Eagle Pharmaceuticals Reports Third Quarter 2019 Results
2019-11-09 14:26:20 | Do Hedge Funds Love Eagle Pharmaceuticals Inc EGRX?